Avacta Group (OTCPK:AVCT.F) - Aandelenkoers, Nieuws & Analyse

AVCT.F Overzicht aandelen

Avacta Group Plc ontwikkelt geneesmiddelen tegen kanker en in-vitro diagnostica in het Verenigd Koninkrijk, Frankrijk, Noord-Amerika, Zuid-Korea, de rest van Europa en internationaal. Meer informatie

AVCT.F fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 2.1% per jaar dalen.

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Avacta Group Plc Concurrenten

Mersana Therapeutics

NasdaqGS:MRSN

US$247.1m

Voyager Therapeutics

NasdaqGS:VYGR

US$314.1m

ProQR Therapeutics

NasdaqCM:PRQR

US$365.3m

Sutro Biopharma

NasdaqGM:STRO

US$215.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Avacta Group
Historische aandelenkoersen
Huidige aandelenkoers	UK£0.65
52 Week Hoogtepunt	UK£2.17
52 Week Laag	UK£0.48
Bèta	1.18
11 maand verandering	-19.95%
3 maanden verandering	-29.45%
1 Jaar Verandering	-58.71%
33 jaar verandering	-55.62%
5 jaar verandering	n/a
Verandering sinds IPO	-54.88%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	AVCT.F	US Biotechs	US Markt
7D	0%	4.0%	2.2%
1Y	-58.7%	18.3%	32.6%

Rendement versus industrie: AVCT.F presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 18.3 % opleverde.

Rendement versus markt: AVCT.F presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.6 % opleverde.

Prijsvolatiliteit

Is AVCT.F's price volatile compared to industry and market?
AVCT.F volatility
AVCT.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van AVCT.F is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van AVCT.F in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2003	154	Chris Coughlin	www.avacta.com

Avacta Group Plc ontwikkelt geneesmiddelen tegen kanker en in-vitro diagnostica in het Verenigd Koninkrijk, Frankrijk, Noord-Amerika, Zuid-Korea, de rest van Europa en internationaal. Het bedrijf opereert via de segmenten Diagnostica en Therapeutica. Het bedrijf biedt zijn eigen Affimer- en pre|CISION-technologieplatforms aan, die worden gebruikt om een portfolio van gedifferentieerde therapeutische en diagnostische producten te leveren voor verschillende markten.

Avacta Group Plc Samenvatting

Hoe verhouden de winst en inkomsten van Avacta Group zich tot de beurswaarde?
AVCT.F fundamentele statistieken
Marktkapitalisatie	US$229.57m
Inkomsten(TTM)	-US$32.48m
Inkomsten(TTM)	US$28.38m

8.1x

P/S-verhouding

-7.1x

Koers/Winstverhouding

Is AVCT.F overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AVCT.F resultatenrekening (TTM)
Inkomsten	UK£22.62m
Kosten van inkomsten	UK£13.10m
Brutowinst	UK£9.52m
Overige uitgaven	UK£35.40m
Inkomsten	-UK£25.89m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.071
Brutomarge	42.08%
Nettowinstmarge	-114.45%
Schuld/Eigen Vermogen Verhouding	49.8%

Hoe presteerde AVCT.F op de lange termijn?

Bekijk historische prestaties en vergelijking

AVCT.F Overzicht aandelen

Risicoanalyse

Avacta Group Plc Concurrenten

NasdaqGS:MRSN

US$247.1m

NasdaqGS:VYGR

US$314.1m

NasdaqCM:PRQR

US$365.3m

NasdaqGM:STRO

US$215.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Recent updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA

Avacta Group plc Announces Results of Initial Evaluation of Sars-Cov-2 Lateral Flow Antigen Test with Clinical Samples

Avacta Group plc Enters into Commercial Partnership with Mologic Ltd

Avacta Announces Collaboration Agreement with Bruker

Avacta Group plc Announces License Agreement with Point Biopharma Inc

Avacta Submits Clinical Trial Application for Ava6000 Pro-Doxorubixin

Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology

Avacta Group plc Announces Significant Progress in Development of a Highly Scalable Manufacturing Process for Lateral Flow SARS-CoV-2 Antigen Test

Avacta Group Plc Launches SARS-CoV-2 BAMS Research Test

Rendement voor aandeelhouders